Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients
BACKGROUND:: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...
| 出版年: | Therapeutic Drug Monitoring |
|---|---|
| 第一著者: | |
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
2013
|
| オンライン･アクセス: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885023351&doi=10.1097%2fFTD.0b013e318290acd2&partnerID=40&md5=ba55042f4bf5b85b4800c13ea9480b73 |